845267-65-4Relevant academic research and scientific papers
First Cdc7 kinase inhibitors: Pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery
Menichincheri, Maria,Bargiotti, Alberto,Berthelsen, Jens,Bertrand, Jay A.,Bossi, Roberto,Ciavolella, Antonella,Cirla, Alessandra,Cristiani, Cinzia,Croci, Valter,D'Alessio, Roberto,Fasolini, Marina,Fiorentini, Francesco,Forte, Barbara,Isacchi, Antonella,Martina, Katia,Molinari, Antonio,Montagnoli, Alessia,Orsini, Paolo,Orzi, Fabrizio,Pesenti, Enrico,Pezzetta, Daniele,Pillan, Antonio,Poggesi, Italo,Roletto, Fulvia,Scolaro, Alessandra,Tato, Marco,Tibolla, Marcellino,Valsasina, Barbara,Varasi, Mario,Volpi, Daniele,Santocanale, Corrado,Vanotti, Ermes
experimental part, p. 293 - 307 (2009/10/09)
Cdc7 kinase is a key regulator of the S-phase of the cell cycle, known to promote the activation of DNA replication origins in eukaryotic organisms. Cdc7 inhibition can cause tumor-cell death in a p53-independent manner, supporting the rationale for devel
PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
-
Page/Page column 37-38, (2010/02/10)
Pyridylpyrrole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treat
PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
-
Page/Page column 28; 29, (2010/02/10)
Pyrimidylpyrrole derivatives of formula (1) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be
